Axsome Therapeutics’ AXSM Auvelity (AXS-05) was launched in the United States in 2022 for the treatment of major depressive disorder (MDD), making it the first approved drug in the company’s portfolio ...

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today ...

Axsome Therapeutics, Inc. has come a long way since its early year as a clinical-stage innovator. The company is enjoying early launch success for its two stellar medicines (Auvelity and Sunosi).

Axsome Therapeutics has entered into a settlement agreement with Hikma resolving patent litigation related to Axsome’s product Sunosi (solriamfetol). The litigation, which is pending in the United ...

Axsome's revenue topped $50 million last year as Sunosi and Auvelity gave the biotech some momentum. The company believes its cash position will sustain it until the business is generating positive ...

Shares of IBD 50 stock Axsome Therapeutics tumbled Tuesday after the biotech reported mixed results for its drug, Sunosi, in adults with attention deficit hyperactivity disorder. The company tested ...

Axsome Therapeutics has reached a settlement agreement with Hetero Labs to resolve a patent dispute related to Hetero Labs’s plans to release a generic of Sunosi, which is a sleep disorder therapy.

Axsome Therapeutics’ AXSM shares have rallied 19.4% in the past month against the industry’s decrease of 0.2%, driven by investor enthusiasm about the company’s encouraging preliminary sales numbers ...

Axsome Therapeutics, Inc. AXSM announced that it has dosed the first patient in the phase III PARADIGM study evaluating its investigational therapy, solriamfetol, for treating major depressive ...